David J Kerr
Overview
Explore the profile of David J Kerr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
4906
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiley M, Bauer J, Alvarez V, Kolics Z, Cheng W, Church D, et al.
Sci Rep
. 2025 Mar;
15(1):8509.
PMID: 40075112
Advanced colorectal cancer (CRC) continues to present with poor survival and treatment options remain limited. We have shown that increased activin A (activin) expression in the tumor microenvironment (TME) is...
2.
Woolley C, Domingo E, Fernandez-Tajes J, Pennel K, Roxburgh P, Edwards J, et al.
Mol Cancer Res
. 2025 Jan;
PMID: 39751654
BRAF mutations in colorectal cancer (CRC) comprise three functional classes: Class 1 (V600E) with strong constitutive activation, Class 2 with pathogenic kinase activity lower than Class 1, and Class 3...
3.
Harris A, Kerr D, Pezzella F, Ribatti D
Trends Cancer
. 2024 Oct;
10(11):1038-1051.
PMID: 39358088
The classic cancer hallmark, inducing angiogenesis, was born out of the long-held notion that tumours could grow only if new vessels were formed. The attempts, based on this premise, to...
4.
Yang L, Yang J, Kleppe A, Danielsen H, Kerr D
Nat Rev Clin Oncol
. 2023 Nov;
21(1):67-79.
PMID: 38001356
The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC) comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in combination with oxaliplatin, for either 3 or...
5.
Frei A, McGuigan A, Sinha R, Glaire M, Jabbar F, Gneo L, et al.
J Pathol Clin Res
. 2023 Sep;
9(6):449-463.
PMID: 37697694
Multiplex immunofluorescence (mIF) imaging can provide comprehensive quantitative and spatial information for multiple immune markers for tumour immunoprofiling. However, application at scale to clinical trial samples sourced from multiple institutions...
6.
Wiley M, Bauer J, Mehrotra K, Zessner-Spitzenberg J, Kolics Z, Cheng W, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296966
We have shown that activin A (activin), a TGF-β superfamily member, has pro-metastatic effects in colorectal cancer (CRC). In lung cancer, activin activates pro-metastatic pathways to enhance tumor cell survival...
7.
Kleppe A, Skrede O, de Raedt S, Hveem T, Askautrud H, Jacobsen J, et al.
Lancet Oncol
. 2022 Aug;
23(9):1221-1232.
PMID: 35964620
Background: The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome...
8.
Barnes E, Brown G, Kerr D
Lancet
. 2022 Jun;
400(10346):78-80.
PMID: 35752195
No abstract available.
9.
Watts K, Wills C, Madi A, Palles C, Maughan T, Kaplan R, et al.
Int J Cancer
. 2022 Apr;
151(6):957-966.
PMID: 35467766
Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia. Genetic variation in ST6GAL1 is a risk factor for type-2 diabetes (T2D), a disease...
10.
Marshall J, Peshkin B, Yoshino T, Vowinckel J, Danielsen H, Melino G, et al.
Oncologist
. 2022 Apr;
27(4):272-284.
PMID: 35380712
Within the last decade, the science of molecular testing has evolved from single gene and single protein analysis to broad molecular profiling as a standard of care, quickly transitioning from...